Current Report Filing (8-k)
May 06 2019 - 04:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2019
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-31361
|
|
35-2089858
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4131 ParkLake Ave., Suite #225
Raleigh, NC
|
|
27612
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
919-582-9050
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation to
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.001
|
|
BDSI
|
|
The Nasdaq Capital Market
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 6, 2019, BioDelivery Sciences International, Inc. (the Company) announced its financial results for the first quarter ended
March 31, 2019. A copy of the press release is being furnished as Exhibit 99.1 to this Form
8-K.
The
information in this Form
8-K
(including Exhibit 99.1) is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such a filing
.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form
8-K,
the press release included herein (and the conference call referred to
in such press release), and any statements of representatives and partners of the Company related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Companys plans, objectives, projections, expectations
and intentions and other statements identified by words such as projects, may, will, could, would, should, believes, expects, anticipates,
estimates, intends, plans, potential or similar expressions. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks
and uncertainties, including those detailed in the Companys filings with the Securities and Exchange Commission. Actual results (including, without limitation, the continued growth in BELBUCA net revenue and total net revenue in 2019 and the
implementation and success of our Symproic strategic plan) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Companys control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by
applicable law.
ONSOLIS
®
,
BUNAVAIL
®
and BELBUCA
®
are registered trademarks of the Company. BUNAVAIL and BELBUCA logos are trademarks owned by the Company. The
Company has an exclusive license to use and display the Symproic registered trademark in order to commercialize Symproic in the United States. All other trademarks and tradenames are owned by their respective owners.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
May 6, 2019
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mary Theresa Coelho
|
|
|
|
|
Name:
|
|
Mary Theresa Coelho
|
|
|
|
|
Title:
|
|
Chief Financial Officer and Treasurer
|
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2023 to Mar 2024